A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0

作者：

Advani, Anjali S. ^{[1
]}

Cooper, Brenda ^{[2
]}

Elson, Paul ^{[3
]}

Mukherjee, Sudipto ^{[4
]}

Fensterl, Jaime ^{[5
]}

Gerds, Aaron T. ^{[6
]}

Caimi, Paolo F. ^{[2
]}

Tomlinson, Ben K. ^{[2
]}

Malek, Ehsan ^{[7
]}

Little, Jane A. ^{[8
]}

Rush, Mary Lynn ^{[9
]}

Bogati, Samjhana ^{[10
]}

Parsons, Eric ^{[9
]}

Kane, Donna ^{[11
]}

Carraway, Hetty E. ^{[4
]}

Nazha, Aziz ^{[6
]}

Hamilton, Betty K. ^{[6
]}

Sobecks, Ronald ^{[12
]}

Bevier, Barbara ^{[9
]}

Goebel, Christopher ^{[9
]}

Zimmerman, Cassie ^{[9
]}

Nielsen, Alek D. ^{[13
]}

Hirsch, Cassandra M. ^{[13
]}

Maciejewski, Jaroslaw P. ^{[13
]}

Kalaycio, Matt ^{[4
]}

deLima, Marcos ^{[14
]}

Jacobberger, James ^{[15
]}

Woost, Philip ^{[15
]}

Sekeres, Mikkael A. ^{[4
,16
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[2] Univ Hosp Case Med Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA

[3] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH USA

[4] Cleveland Clin, Taussig Canc Inst Leukemia Program, Cleveland, OH USA

[5] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA

[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[7] Univ Hosp Case Med Ctr, Cleveland, OH USA

[8] Case Western Reserve Univ Univ Hosp Seidman Canc, Div Hematol Oncol, Cleveland, OH USA

[9] Cleveland Clin Leukemia Program, Taussig Canc Inst, Cleveland, OH USA

[10] Cleveland Clin Taussig Canc Inst, Taussig Canc Inst Leukemia Program, Cleveland, OH USA

[11] Univ Hosp Cleveland, Seidman Canc Ctr, Cleveland, OH USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA

[13] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[14] Univ Hosp, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA

[15] Case Western Reserve Univ, Cleveland, OH USA

[16] Cleveland Clin, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4065.4065

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4065

引用

页数：5

共 50 条

[31] Phase I/II study of escalating doses of mitoxantrone in a single injection combined with timed sequential therapy with cytarabine and etoposide in patients with refractory or relapsed acute myeloid leukemia (AML).
Thomas, X
Cambier, N
Taksin, AL
Reman, O
Vekhoff, A
Cordonnier, C
Leblond, V
Soler-Michel, P
Ecstein-Fraïssé, E
Archimbaud, E
BLOOD, 1999, 94 (10) : 238B - 238B
[32] Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
Bhatnagar, Bhavana
Walker, Alison R.
Mims, Alice S.
Vasu, Sumithira
Klisovic, Rebecca B.
Behbehani, Gregory
Blachly, James Stewart
Larkin, Karilyn T. M.
Long, Meixiao
Zhao, Qiuhong
Ranganathan, Parvathi
Byrd, John C.
Blum, William G.
Garzon, Ramiro
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
Norbert Vey
Hagop Kantarjian
Miloslav Beran
Susan O'Brien
Jorge Cortes
Charles Koller
Elihu Estey
Investigational New Drugs, 1999, 17 : 89 - 95
[34] Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995).
Greenberg, P
Advani, R
Tallman, M
Letendre, L
Saba, H
Dugan, K
Lee, SJ
Lum, B
Sikic, BI
Paietta, E
Bennett, J
Rowe, JM
BLOOD, 1999, 94 (10) : 383A - 383A
[35] AS1411 IN COMBINATION WITH CYTARABINE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
Stuart, K.
Stockerl-Goldstein, K.
Cooper, M.
Devetten, M.
Herzig, R.
Medeiros, B.
Schiller, G.
Wei, A.
Acton, G.
Rizzieri, D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 336 - 336
[36] COMBINATION OF CLOFARABINE AND CYTARABINE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
Spassov, B.
Balatzenko, G.
Angelova, S.
Toshkov, S.
Guenova, M.
Arnaudov, G.
Mihaylov, G.
HAEMATOLOGICA, 2015, 100 : 377 - 377
[37] MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia
Marconi, Giovanni
Talami, Annalisa
Abbenante, Maria Chiara
Sartor, Chiara
Parisi, Sarah
Nanni, Jacopo
Bertamini, Luca
Ragaini, Simone
Olivi, Matteo
de Polo, Stefano
Cristiano, Gianluca
Fontana, Maria Chiara
Bochicchio, Maria Teresa
Ottaviani, Emanuela
Arpinati, Mario
Sessa, Mariarosaria
Baldazzi, Carmen
Caso, Lucia
Testoni, Nicoletta
Baccarani, Michele
Bonifazi, Francesca
Martinelli, Giovanni
Paolini, Stefania
Cavo, Michele
Papayannidis, Cristina
Curti, Antonio
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (01) : 47 - 55
[38] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Naqvi, Kiran
Ravandi, Farhad
Kantarjian, Hagop
Borthakur, Gautam
Ferrajoli, Alessandra
Thomas, Deborah A.
Koller, Charles Asa
Konopleva, Marina
Byrd, Anna
Kwari, Monica
Faderl, Stefan
BLOOD, 2010, 116 (21) : 464 - 465
[39] PHASE 1 PHARMACOKINETIC (PK) STUDY OF IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE AND DEXAMETHASONE IN ASIAN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Gupta, N.
Goh, Y. T.
Min, C. K.
Lee, J. H.
Suh, C.
Kim, K.
Wong, R.
Chim, J.
Hanley, M. J.
Yang, H.
Venkatakrishnan, K.
Hui, A. M.
Schusterbauer, C.
Chng, W. J.
HAEMATOLOGICA, 2014, 99 : 372 - 372
[40] Treatment of elderly acute myeloid leukemia (AML) patients with the combination of mitoxantrone and cytarabine (MAC).
Marinakis, T
Galanopoulos, AG
Zomas, A
Michalis, E
Gortzolidis, G
Tsakiridou, A
Xanthopoulos, V
Theodoropoulos, G
Goumakou, H
Georgiakaki, M
Grigoraki, V
Anagnostopoulos, NI
BLOOD, 2005, 106 (11) : 235B - 235B

← 1 2 3 4 5 →